Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005 Dec;2(12):e417.
doi: 10.1371/journal.pmed.0020417. Epub 2005 Dec 27.

Breaking up (amyloid) is hard to do

Affiliations
Comment

Breaking up (amyloid) is hard to do

Sam Gandy et al. PLoS Med. 2005 Dec.

Abstract

Gandy and Heppner discuss the implications of a new animal study on our understanding of the pathogenesis and treatment of Alzheimer disease.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SG is an advisor to Elan Pharmaceuticals, and receives grant support from the Robert Atkins Foundation. He is Chair of the National Medical and Scientific Advisory Council of the United States Alzheimer's Association. FLH declares that he has no competing interests.

Figures

Figure 1
Figure 1. A Large Energy Barrier Prevents Rapid Redissolution of Fibrillar Amyloid
In this issue of PLoS Medicine, Borchelt and colleagues demonstrate in the living amyloid-laden mouse brain that Aβ plaques are cleared very slowly, even if synthesis of new Aβ precursor molecules is extinguished using a tet-off system [7]. In the recent, relevant, but independent, X-ray crystallography study [8], Nelson et al. envisioned the free-energy plot shown above as a graphic description of the kinetics of transition from monomeric Aβ to fibrillar Aβ (ΔGformation). For the reverse reaction, Nelson et al. envision the ΔGdissolution as the large free-energy barrier to spontaneous solubilization of amyloid fibrils. Presumably, it is this ΔGdissolution that underlies the slow disappearance of brain plaques in the Borchelt study in transgenic mice. (Illustration: Sapna Khandwala, adapted from [8])

Comment on

References

    1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde.”. Clin Anat. 1995;8:429–431. - PubMed
    1. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890. - PubMed
    1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245–4249. - PMC - PubMed
    1. Davies P. Biochemical changes in Alzheimer's disease-senile dementia: Neurotransmitters in senile dementia of the Alzheimer's type. Res Publ Assoc Res Nerv Ment Dis. 1979;57:153–166. - PubMed
    1. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7:369–372. - PubMed

Publication types

Substances